Zymergen lands $400 million more for its genetically altered microbes, led by SoftBank Vision Fund

Dec 13, 2018 - TechCrunch

Zymergen, a five-year-old company that manufacturers molecules for a wide array of uses and industries, has closed on $400 million in Series C funding led by one of its earlier investors, the SoftBank Vision Fund.

Even in a world where triple-digit million-dollar rounds have become de rigueur, the amount stands out, as does the company, which occupies a 301,000-square-foot campus in Emeryville, Ca. and has been growing like gangbusters. How? By engineering yeast and ...